期刊
CLINICAL SCIENCE
卷 116, 期 1-2, 页码 17-26出版社
PORTLAND PRESS LTD
DOI: 10.1042/CS20070462
关键词
chronic kidney disease; diabetic nephropathy; peroxisome-proliferator-activated receptor(PPAR); renoprotection; Type 2 diabetes
资金
- NSFC (Natural Science Foundation of China) [30670766, 30530340, 30771030]
- Ministry of Science and Technology of China [2006CB503907]
DN (diabetic nephropathy) is a chronic disease characterized by proteinuria, glomerular hypertrophy, decreased glomerular filtration and renal fibrosis with loss of renal function. DN is the leading cause of ESRD (end-stage renal disease), accounting for millions of deaths worldwide. TZDs (thiazolidinediones) are synthetic ligands of PPAR gamma (peroxisome-proliferator-activated receptor gamma), which is involved in many important physiological processes, including adipose differentiation, lipid and glucose metabolism, energy homoeostasis, cell proliferation, inflammation, reproduction and renoprotection. A large body of research over the past decade has revealed that, in addition to their insulin-sensitizing effects, TZDs play an important role in delaying and preventing the progression of chronic kidney disease in Type 2 diabetes. Although PPAR gamma activation by TZDs is in general considered beneficial for the amelioration of diabetic renal complications in Type 2 diabetes, the underlying mechanism(s) remains only partially characterized. In this review, we summarize and discuss recent findings regarding the renoprotective effects of PPAR gamma in Type 2 diabetes and the potential underlying mechanisms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据